Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 1007-1010

  Douet Guilbert, Nathalie ^a,b,c   Herry, Angèle ^a   Le Bris, Marie Josée ^b   Guéganic, Nadia ^a   Bovo, Clément ^a   Morel, Frédéric ^a,b,c   De Braekeleer, Marc ^a,b,c  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b CHU MORVAN   (France)

^c INSERM   (France)

Author keywords

Del(20q); Del(5q); Interphase FISH; MDS; Normal karyotype

Indexed keywords

20Q SYNDROME; 5Q- SYNDROME; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CELL GROWTH; CHROMOSOME 20Q; CHROMOSOME 5Q; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; INTERPHASE; KARYOTYPE; MAJOR CLINICAL STUDY; METAPHASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KARYOTYPING; MYELODYSPLASTIC SYNDROMES;

EID: 79956093053     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Raskind WH, Steinmann L and Najfeld V: Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia 12: 108-116, 1998. (Pubitemid 28108059)
2. Hofmann WK and Koeffler HP: Myelodysplasic syndrome. Annu Rev Med 56: 1-16, 2005.
3. Vallespi T, Imbert M, Mecucci C, Preudhomme C and Fenaux P: Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83: 258-275, 1998. (Pubitemid 28209132)
4. Fenaux P, Morel P and Lai JL: Cytogenetics of myelodysplastic syndromes. Semin Hematol 33: 127-138, 1996.
5. Ketterling RP, Wyatt WA, VanWier SA, Law M, Hodnefield JM, Hanson CA and Dewald GW: Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. Leukemia Res 26: 235-240, 2002.
6. Skonieczka K, Duszenko E, Wyrowinska E and Haus O: Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes. Pol Arch Med Wewn 119: 366-372, 2009.
7. Shali W, Helias C, Fohrer C, Struski S, Gervais C, Falkenrodt A, Leymarie V, Lioure B, Raby P, Herbrecht R and Lessard M: Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet 168: 133-145, 2006.
8. Rigolin GM, Bigoni R, Milani R, Cavazzini F, Roberti MG, Bardi A, Agostini P, della Porta M, Tieghi A, Piva N, Cuneo A and Castoldi G: Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 15: 1841-1847, 2001.
9. Jenkins RB, Le Beau MM, Kraker WJ, Borell TJ, Stalboerger PG, Davis EM, Penland L, Fernald A, Espinosa R and Schaid DJ: Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 79: 3307-3315, 1992.
10. Kibbelaar RE, Mulder JW, Dreef EJ, van Kamp H, Fibbe WE, Wessels JW, Beverstock GC, Haak HL and Kluin PM: Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a comparison of banding and fluorescence in situ hybridization. Blood 82: 904-913, 1993. (Pubitemid 23221674)
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199, 1982.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625, 1985.
13. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW and Harris NL: Myelodysplastic syndromes, acute myeloid leukaemias. In: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Jaffe ES, Harris NL, Stein H, and Vardiman JW (eds.). Lyon, IARC Press, pp. 61-107, 2001.
14. ISCN (2009): An International System for Human Cytogenetic Nomenclature. Basel, S. Karger, 2009.
15. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F and Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315-1323, 1993.
16. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G and Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088, 1997. (Pubitemid 27132124)
17. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C and Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25: 3503-3510, 2007. (Pubitemid 47315575)
18. Royer-Pokora B, Trost D, Muller N, Hildebrandt B, Germing U and Beier M: Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodysplastic syndromes and acute myeloid leukemia. Cancer Genet Cytogenet 167: 66-69, 2006.
19. Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, Germing U, Royer HD and Royer-Pokora B: Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chrom Cancer 46: 1119-1128, 2007. (Pubitemid 47614546)
20. Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C and De Braekeleer M: Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia, chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87: 537-544, 2008.
21. Wilkens L, Burkhardt D, Tchinda J, Busche G, Werner M, Nolte M, Ganser A and Georgii A: Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization. Diagn Mol Pathol 8: 47-53, 1999. (Pubitemid 29300250)
22. Romeo M, Chauffaille M, Silva M, Bahia D and Kerbauy J: Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leukemia Res 26: 993, 2002.
23. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, Bennett JM, Greenberg PL, Miller K, Tallman MS, Rowe J and Dewald GW: Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leukemia Res 27: 1085-1090, 2003. (Pubitemid 36960027)
24. Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I, Rocca B, Crosetto N, Caresana M, Lazzarino M and Bernasconi C: Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17: 2107-2112, 2003. (Pubitemid 37428375)
25. Beyer V, Castagne C, Muhlenmatter D, Parlier V, Gmur J, Hess U, Kovacsovics T, Meyer-Monard S, Tichelli A, Tobler A, Jacky E, Schanz U, Bargetzi M, Hagemeijer A, de Witte T, Van Melle G and Jotterand M: Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet 152: 29-41, 2004.
26. Yilmaz Z, Sahin FI, Kizilkilic E, Karakus S, Boga C and Ozdogu H: Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. Clin Exp Med 5: 55-59, 2005. (Pubitemid 41153363)
27. Mallo M, Arenillas L, Espinet B, Salido M, Hernandez MA, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, Gonzalez O, Renedo M, Cervera J, Such E, Sanz GF, Luno E, Sanzo C, Gonzalez M, Calasanz MJ, Mayans J, Garcia-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yanez L, Muruzabal MJ, Gomez-Beltran E, Andreu R, Leon P, Gomez V, Sanz A, Casasola N, Moreno E, Alegre A, Martin ML, Pedro C, Serrano S, Florensa L and Sole F: FISH improves the detection of 5q31 deletion in myelodysplastic syndromes (MDS) without cytogenetic evidence of 5q-. Haematologica 93: 1001-1008, 2008. (Pubitemid 351957017)
28. Yang W, Stotler B, Sevilla DW, Emmons FN, Murty VV, Alobeid B and Bhagat G: FISH analysis in addition to G-band karyotyping: Utility in evaluation of myelodysplastic syndromes? Leukemia Res 34: 420-425, 2010.
29. Sun Y and Cook JR: Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: Comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone. Leukemia Res 34: 340-343, 2010.